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Abstract: Pegylated liposomal doxorubicin (PLD) has been widely used to treat cancer. The 
adverse effects of PLD noted in clinical practice, especially hand-foot syndrome (HFS), are 
regarded as unique, and the management methods for them remain limited. This study was aimed 
at developing a feasible experimental model for translational medicine to solve this clinical 
issue by using skin fluorescent transgenic zebrafish. We established an optimal protocol for the 
administration of Lipo-Dox™, a PLD in current clinical use, to the Tg(k18:dsred) zebrafish 
line expressing red fluorescence in keratinocytes. We made use of bodyweight, survival rate, 
gross observation, flssuorescent microscopic assessment, and pathological examination of the 
zebrafish to assess this model. The consecutive administration protocol of PLD resulted in 
growth retardation of the zebrafish embryo and survival impairment, indicating establishment 
of a significant toxicity. We observed fin necrosis and keratinocyte dissociation phenotypes in 
the PLD-treated fish after consecutive administration. The skin toxicity induced by the Lipo-
Dox injection was subsequently reversible, which might be compatible with a clinical course of 
skin recovery after discontinuation of Lipo-Dox administration. Furthermore, we found that the 
number of intestinal goblet cells, an important marker of intestinal inflammation, in the Lipo-
Dox-injected zebrafish was markedly increased, accompanied by impaired mucosal integrity. 
The intestinal inflammation induced by Lipo-Dox resembled the intestinal mucositis the clinical 
patients suffered from after the administration of PLD. In conclusion, we established a zebrafish 
model for PLD-induced HFS. The intestinal mucositis simultaneously noted in the PLD-treated 
zebrafish validated the similarity of clinical courses after administration of PLD. This model 
is easily assessable, efficient, and worthy for use in developing a new therapeutic protocol for 
prevention or treatment of HFS as well as intestinal mucositis. Further clinical investigations 
to validate the correlation between human and zebrafish data are warranted.
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Introduction
Pegylated liposomal doxorubicin (PLD) has been widely used in the treatment of 
various types of cancers including ovarian,1 breast,2 and acquired immunodeficiency 
syndrome (AIDS)-related Kaposi’s sarcoma.3 A Phase III trial for patients with 
platinum-sensitive relapsed/recurrent ovarian cancer demonstrated superiority in 
progression-free survival and a better therapeutic index for a combination of PLD 
with carboplatin in comparison with standard paclitaxel and carboplatin.4
PLD nanoparticles are doxorubicin hydrochloride encapsulated in pegylated 
liposomes. PLD is composed of distearoyl phosphatidylcholine and formulated with 
surface-bound methoxy polyethylene glycol, as for pegylation, to protect liposomes 
from detection by the mononuclear phagocytes and to increase blood circulation time.5 
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PLD displays linear pharmacokinetics over the dose range 
of 10–20 mg/m2 and nonlinear at a dose of 50 mg/m2. The 
plasma clearance of PLD is slow, and the area under the curve 
is approximately two to three orders of magnitude larger than 
a similar dose of free-form doxorubicin.6 The incidence of 
cardiotoxicity may be lower after PLD than after equivalent 
doses of standard doxorubicin.7
Among the adverse effects of PLD, hand-foot syndrome 
(HFS, also known as “palmar-plantar erythrodysesthesia”) 
and intestinal mucositis8–10 often cause infection or severe 
pain, and may induce lethal gastrointestinal bleeding. 
HFS, especially, is the most common side effect which 
compromises patients’ quality of life. The typical pathologi-
cal changes of HFS include reddening, swelling, and desqua-
mation on palms and soles.11 To date, the known protocols 
for prevention or treatment of HFS are limited except for one 
protocol describing that cooling the hands and feet during 
PLD therapy may help relieve the HFS symptoms.12 In this 
regard, establishing an animal model of HFS is an important 
step for developing agents to prevent or treat HFS.
The zebrafish has been accepted as a feasible model 
for toxicological study.13 There are abundant fluorescent 
zebrafish lines available to detect and observe subtle changes 
on tissue level grossly.14,15 For example, a green fluorescent 
kidney [Tg(wt1b:GFP)] and a red fluorescent skin transgenic 
zebrafish line [Tg(k18:dsred)] have been reported to evalu-
ate the toxic effects on kidney and skin.15,16 This advantage 
makes observation for phenotypic alterations of target tissues 
convenient and specific.
In this study, we established a zebrafish model for 
 PLD-induced HFS and intestinal mucositis. The gross 
 feature with quantitation and the pathological changes in skin 
 fluorescent transgenic zebrafish were demonstrated.
Materials and methods
Zebrafish
To investigate the adverse effects of PLD in a zebrafish 
model, we obtained a skin fluorescent transgenic zebrafish 
line established by Professor HJ Tsai,17,18 Tg(k18:dsred), from 
Tsai’s lab and raised them to 0.1–0.2 g (around 35–42 days 
post-fertilization) before the experiment.
chemicals and PlD administration
The PLD used in this study, Lipo-Dox™ (20 mg/10 mL), 
was purchased from TTY Biopharm (Taipei, Taiwan). For 
drug treatment, the Tg(k18:dsred) zebrafish were dosed 
(by  intraperitoneal injection) either without Lipo-Dox 
(buffer only; mock-control group, n=6) or with a buffer 
 containing 40 µg/g of Lipo-Dox (Lipo-Dox-injected group, 
[n=12, #1–#12]). The injection protocol is summarized in 
Figure 1. In brief, we injected Lipo-Dox one dose (40 µg/g) 
at day 0, and subsequently injected one dose per week for 
4 weeks (days 7, 14, 21, and 28), and examined the zebrafish 
 phenotypic defects at each check point (days 10, 17, 24, 31, 
38, 45, and 51).
gross and microscopic assessment  
of phenotype
All of the fish samples were observed under a microscope 
(DM 2500, Leica; Buffalo Grove, NY, USA) equipped with a 
fluorescent DsRed filter cube (Kramer Scientific, Amesbury, 
MA, USA), and we captured pictures of the fish at particular 
stages using a digital camera (Sony, Tokyo, Japan).
Pathological examination
For pathological examination, the zebrafish were fixed in 
formalin and embedded in paraffin. Sections of 5 µm were 
cut, deparaffinized, rehydrated, and stained with hematoxylin 
and eosin Y. A pathologist blinded to which experimental 
group the specimens were from evaluated the slides and 
reported the comparison results.18,19
statistics
The Kaplan–Meier method was used to depict the curves for the 
cumulative survival rates of embryos in the control and Lipo-
Dox-injected groups. To assess the effect of drug on the increase 
of weight, we fitted the following linear regression model: 
weight {initial weight} time group= + + + +β β β β0 1 2 3{ } { }
error ; where b
0
 is the intercept of the model, b
1
 is the 
Tg(k18:dsred) zebrafish
Intraperitoneal
injection
Check points
10 17 24 31 38 45 51 (days)
0 7 14 21 28
Experimental group: injection of Lipo-Dox (40 µg/g)
Mock control group: injection of buffer only
Figure 1 schematic representation of experimental protocols performed in this study.
Notes: Tg(k18:dsred) zebrafish were intraperitoneally injected either with buffer 
only (mock-control group, n=6) or with buffer containing 40 µg/g of lipo-Dox 
(Lipo-Dox™-injected group, n=12, #1–#12). We injected Lipo-Dox one dose (40 
µg/g) at day 0, and subsequently injected one dose per week for 4 weeks (days 7, 
14, 21, and 28), and examined the zebrafish phenotypic defects at each check point 
(days 10, 17, 24, 31, 38, 45, and 51).
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 regression coefficient associated with initial weight (the 
weight at the beginning of the observation period, week 0), 
b
2
 is the regression coefficient associated with time (the weeks 
after exposure to drug), and b
3
 is the regression coefficient 
associated with group (group =1 for the drug group and 0 
for the control group). Note that the measurements on the 
weight from the same embryo are correlated. To account for 
the within-embryo correlation, we applied the generalized 
estimating equation (GEE) analysis20 to estimate the param-
eters in the above model, assuming a normal distribution and a 
first-order autoregressive correlation structure for the data.
Results
gross assessment of hFs and intestinal  
mucositis in zebrafish model
The results showed that the zebrafish receiving no Lipo-Dox 
(mock control) had a smooth belly and a regular-shaped 
caudal fin (Figure 2A–E). The Lipo-Dox-injected zebrafish 
had no apparent phenotypic changes at the first three check 
points (days 10, 17, and 24), but intriguingly, displayed 
abdominal hemorrhage and fin fester, especially in the caudal 
fin regions at day 31 (Figure 2A′–E′). Thus, the most obvious 
Lipo-Dox-induced phenotypes that can be observed grossly 
are abdominal hemorrhage and fin necrosis.
We observed fin necrosis and keratinocyte dis sociation 
phenotypes in another two fish (#5 and #6) in the later stages 
(by days 38, 45, and 51) after discontinuation of Lipo-Dox 
administration (the latest injection was at day 28, Figure 1). 
Extensive fin necrosis at the caudal region was observed 
by day 38, but gradually recovered by days 45 and 51 (Fig-
ure 3A-I versus B-I and C-I; Figure 3D-I  versus E-I and 
F-I; indicated by arrows). Using fluorescent microscopy, 
we found that red fluorescent keratinocytes were aligned 
normally in the control zebrafish (data not shown), but 
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Figure 2 Abdominal hemorrhage and fin necrosis are observed in zebrafish embryos after Lipo-Dox™ injection.
Notes: (A–E) Mock control. (A'–E') Tg(k18:dsred) zebrafish (#2) was injected with buffer containing 40 µg/g of lipo-Dox.
OncoTargets and Therapy 2014:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1172
chen et al
Tg (k18:dsred)
Check points
(days)
38
A-I D-I
E-I
F-I
A-II
B-II
C-II F-II
E-II
D-II
B-I
C-I
45
51
Epidermis
Lipo-Dox (#5) Lipo-Dox (#6)
Caudal fin
Figure 3 Effects of Lipo-Dox™ on the zebrafish’s caudal fin (I) and epidermis (II).
Notes: Lipo-Dox-injected Tg(k18:dsred) zebrafish (#5 and #6) were observed under microscopy with bright field (A-I–F-I) or an RFP filter (A-II–F-II). Fin necrosis (arrow 
indicates) and keratinocyte dissociation are the evident phenotypes in the Lipo-Dox-injected zebrafish.
Abbreviation: RFP, red fluorescent protein.
A B C
FED
M
o
ck
 c
o
n
tr
o
l
L
ip
o
-D
o
x 
(#
2)
Figure 4 Histological examination of Lipo-Dox™-injected embryos.
Notes: Fish derived from the mock control (A–C) or Lipo-Dox-injected groups (D–F) were transverse sectioned and stained with hematoxylin/eosin Y. (A and C) lateral 
side; (B and E) Ventral region; (C and F) intestine. Yellow star indicates the position of goblet cell. Black arrows indicate the positions of epidermis lesions.
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appeared in a patch-like shape or even invisible on the 
surface (Figure 3A-II versus B-II). Those red fluorescent 
keratinocyte abnormalities gradually recovered by days 45 
and 51 (Figure 3C-II, D-II, E-II, and F-II), compatible with 
the gross finding.
Pathological examination  
of abdominal skin and intestines
We next carried out paraffin sectioning and  hematoxylin/
eosin Y staining experiments to further dissect the 
 Lipo-Dox-induced abdominal hemorrhage phenotypes from 
the histological level. The results showed that several mucosa 
cells appeared in the skin epidermis, but very few goblet 
cells were observed in the intestine region in the mock-
treated control zebrafish (Figure 4A–C). However, missing 
mucosa cells with impaired mucosal integrity, thinner skin 
epidermis, and increased numbers of goblet cells (a marker 
for intestine inflammatory reaction) were observed in the 
Lipo-Dox-injected zebrafish (Figure 4D–F).
Growth retardation of zebrafish
We noticed that the Lipo-Dox-injected zebrafish larvae 
exhibited various degrees of growth retardation and impaired 
survival. For growth retardation, Table 1 displays the analysis 
result by GEE model. It shows that the growth, estimated 
by weight, in the Lipo-Dox-injected group was significantly 
less than the control group (P=0.010). The embryos in the 
Lipo-Dox-injected group tended to have a lower weight of 
0.033 g (with a standard error of 0.013 g) than those in the 
control group, adjusting the time after exposure to Lipo-Dox 
and the initial weight by the GEE method.
Survival analysis of zebrafish
We first applied the Kaplan–Meier method to depict the 
survival curves of embryos in the control and Lipo-Dox-
injected groups. As shown in Figure 5, a 25% death rate 
at the end of study, 7.43 weeks after exposure to drug, in 
the Lipo-Dox-injected group was noted. The mean survival 
time for the Lipo-Dox-injected group was 5.26±0.13 weeks. 
Table 1 generalized linear regression based on the gee method for assessing the effect of lipo-Dox™ on the weight growth rates 
of embryos
Variable Estimate Standard 
error
z-value P-value Lower CL Upper CL
intercept 0.037 0.043 0.877 0.381 -0.046 0.120
initial weight 
group
1.340 
-0.033
0.286 
0.013
4.681 
-2.587
,0.001 
0.010
0.779 
-0.058
1.901 
-0.008
Abbreviations: CL, confidence level; GEE, generalized estimating equation.
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Figure 5 Kaplan–Meier estimates of survival curves for the mock control and Lipo-Dox™-injected groups.
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No embryos died in the control group. The log-rank test was 
further utilized to examine the homogeneity of the death rate 
curves for the two groups. The result shows a significant dif-
ference in time to death between the groups (P-value =0.043), 
confirming the Lipo-Dox-injected group had suffered a 
significant harmful effect.
Conclusion
In the zebrafish model we established for gross assessment 
of PLD-induced HFS, we observed both the intestinal 
mucositis, a common side effect of PLD in humans, as well 
as skin  damage with the typical pathological changes of 
HFS, validating that this model is clinically feasible due 
to the similarities in the clinical course and manifestations. 
The toxicity induced by Lipo-Dox injection was reversible, 
as is the case in clinical practice, where the typical skin 
 pathological changes of HFS disappear within a few weeks 
after discontinuation of the drug.12
The markedly increased number of intestinal goblet cells 
(an important marker of intestinal inflammation)21,22 we 
observed in the Lipo-Dox-injected zebrafish suggest that the 
intestinal inflammation induced by Lipo-Dox resembles the 
intestinal mucositis the clinical patients suffered from after 
the administration of this anticancer therapeutic.
Our data suggest that the zebrafish can be regarded as an 
efficient screening model for agents managing PLD-induced 
HFS, as well as intestinal mucositis. However, further  clinical 
investigations to validate the correlation between human and 
zebrafish data are warranted.
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